PharmScience Logo
Register Now
Background

Abstract Submission

Abstract Template

Scientific Sessions

Explore our diverse range of research tracks and topics.

Pharmacology
Biopharmaceutics
Pharmaceutics
Biotechnology in Pharmacy
Drug Discovery & Development
Pharmacology & Toxicology
Drug Screening & Designing
Pharmaceutical Product Development
Pre-clinical Research
Pharmaceutical Chemistry
Drug Delivery Systems
Artificial Intelligence in R&D
Nanomedicine
Industrial Pharmacy
Pharmaceutical Manufacturing
Quality Control & Quality Assurance
Clinical Trails & Case Studies
Pharmacotherapeutics
Regulatory & HTA Review
FDA Approvals
Product Management
Market Prediction
Existing Drugs Enhancement
Pharmaceutical Statistics
Pharmaceutical Analysis
Pharmacogenomics
Natural Product Chemistry
Safety & Monitoring
Personalized Medicine
Education & Practice

Encore Abstract Acceptance Guidelines

Encore abstracts may be considered for presentation provided that the submitting authors comply with the conference requirements and meet the following criteria:

01

Prior Presentation

The abstract or substantially similar findings may have been previously presented at another scientific meeting. Authors must disclose the prior presentation, including the conference name, date/year, and abstract or presentation number, if applicable.

02

Additional Scientific Value

Encore submissions should include substantial additional data, analyses, follow-up, or scientific interpretation that provides meaningful value beyond the original presentation, where applicable.

03

Avoidance of Duplicate Presentation

Encore abstracts should not simply reproduce the same findings for essentially the same audience. Consideration will be given to whether the new meeting provides a substantially different geographic, professional, or scientific audience.

04

Disclosure of Encore Status

Authors must clearly identify the submission as an encore presentation during the abstract submission process. If accepted, the prior presentation should also be appropriately acknowledged in the presentation materials.

05

Copyright and Publication Rights

Authors are responsible for ensuring that the submission and reproduction of previously presented or published material comply with applicable copyright, publication, and conference policies. Where necessary, permission must be obtained from the relevant copyright holder or publisher.

06

Substantial Modification

If additional data or analyses substantially change the research question, methodology, results, or conclusions, the abstract may be considered a new/original abstract rather than an encore abstract.

07

Scientific Integrity

Encore submissions must meet the same standards for scientific quality, accuracy, transparency, authorship, and ethical conduct as all other abstract submissions.

08

Conference Discretion

Acceptance of an encore abstract is at the discretion of the Scientific/Organizing Committee, which may request clarification regarding the original presentation, additional data, or the rationale for the encore submission.

PharmScience Logo

The 9th International Conference of PharmScience Research & Development, organized by USG United Scientific Group, a non-profit organization based in Plano, Texas, USA, will be held from February 17–19, 2027, in Houston, Texas.

Organised By

USG United Scientific Group

A non-profit organization
8105 Rasor Blvd, Suite 112
Plano, TX 75024, USA

pharma-rnd@uniscigroup.net
contact@unitedscientificgroup.org

Subscribe to our Newsletter

Copyright © 2027, USG United Scientific Group. All Right Reserved